Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk

Key Points

Question  Is aspirin use associated with a reduction in colorectal cancer (CRC) incidence across a continuum of established lifestyle factors?

Findings  In this cohort study of 107 655 men and women receiving aspirin and followed up for more than 3 decades, the absolute reduction in CRC risk was more pronounced among those with an unhealthier lifestyle (ie, higher body mass index, greater amount of smoking, higher alcohol intake, less physical activity, and poorer diet quality) compared with those with a healthier lifestyle. In contrast, the relative reduction in CRC risk associated with aspirin use was similar.

Meaning  The findings of this study suggest that aspirin may be useful for CRC prevention for individuals with additional risk factors.

Abstract

Importance  Aspirin reduces the risk of colorectal cancer (CRC). Identifying individuals more likely to benefit from regular aspirin use for CRC prevention is a high priority.

Objective  To assess whether aspirin use is associated with the risk of CRC across different lifestyle risk factors.

Design, Setting, and Participants  A prospective cohort study among women in the Nurses’ Health Study (1980-2018) and men in the Health Professionals Follow-Up Study (1986-2018) was conducted. Data analysis was performed from October 1, 2021, to May 22, 2023.

Exposures  A healthy lifestyle score was calculated based on body mass index, alcohol intake, physical activity, diet, and smoking with scores ranging from 0 to 5 (higher values corresponding to a healthier lifestyle). Regular aspirin use was defined as 2 or more standard tablets (325 mg) per week.

Main Outcome and Measures  Outcomes included multivariable-adjusted 10-year cumulative incidence of CRC, absolute risk reduction (ARR), and number needed to treat associated with regular aspirin use by lifestyle score and multivariable-adjusted hazard ratios for incident CRC across lifestyle scores.

Results  The mean (SD) baseline age of the 107 655 study participants (63 957 women from the Nurses’ Health Study and 43 698 men from the Health Professionals Follow-Up Study) was 49.4 (9.0) years. During 3 038 215 person-years of follow-up, 2544 incident cases of CRC were documented. The 10-year cumulative CRC incidence was 1.98% (95% CI, 1.44%-2.51%) among participants who regularly used aspirin compared with 2.95% (95% CI, 2.31%-3.58%) among those who did not use aspirin, corresponding to an ARR of 0.97%. The ARR associated with aspirin use was greatest among those with the unhealthiest lifestyle scores and progressively decreased with healthier lifestyle scores (P < .001 for additive interaction). The 10-year ARR for lifestyle scores 0 to 1 (unhealthiest) was 1.28%. In contrast, the 10-year ARR for lifestyle scores 4 to 5 (healthiest) was 0.11%. The 10-year number needed to treat with aspirin was 78 for participants with lifestyle scores 0 to 1, 164 for score 2, 154 for score 3, and 909 for scores 4 to 5. Among the components of the healthy lifestyle score, the greatest differences in ARR associated with aspirin use were observed for body mass index and smoking.

Conclusions and Relevance  In this cohort study, aspirin use was associated with a greater absolute reduction in risk of CRC among individuals with less healthy lifestyles. The findings of the study suggest that lifestyle risk factors may be useful to identify individuals who may have a more favorable risk-benefit profile for cancer prevention with aspirin.

Source

Also:  Study finds regular aspirin use associated with greatest reduction in colorectal cancer among those most at risk &

          Daily Aspirin Cuts Odds for Colon Cancer: Who Benefits Most?